Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

June 25, 2024 3:30 PM EDT

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapy
Follow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28 in the three patients who previously received the lowest dose in the Phase 1 dose-escalation study55 mg follow-on dose was well tolerated across all patients While redosing is not planned for the NTLA-2001 program in transthyretin (ATTR) amyloidosis, a redosing option could be an important advantage of Intellias non-viral, lipid nanoparticle (LNP)-based delivery platform for future investigational therapies where a target... More